• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

造血干细胞移植后死亡:随时间推移的变化、感染及相关因素。

Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors.

机构信息

Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.

Policlinico G.B. Rossi, Verona, Italy.

出版信息

Bone Marrow Transplant. 2020 Jan;55(1):126-136. doi: 10.1038/s41409-019-0624-z. Epub 2019 Aug 27.

DOI:10.1038/s41409-019-0624-z
PMID:31455899
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC6957465/
Abstract

Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55'668 deaths in 114'491 patients with HSCT (83.7% allogeneic) for leukemia were investigated in a landmark analysis for causes of death at day 30 (very early), day 100 (early), at 1 year (intermediate) and at 5 years (late). Mortality from all causes decreased from cohort 1 (1980-2001) to cohort 2 (2002-2015) in all post-transplant phases after autologous HSCT. After allogeneic HSCT, mortality from infections, GVHD, and toxicity decreased up to 1 year, increased at 5 years; deaths from relapse increased in all post-transplant phases. Infections of unknown origin were the main cause of infectious deaths. Lethal bacterial and fungal infections decreased from cohort 1 to cohort 2, not unknown or mixed infections. Infectious deaths were associated with patient-, disease-, donor type, stem cell source, center, and country- related factors. Their impact varied over the post-transplant phases. Transplant centres have successfully managed to reduce death after HSCT in the early and intermediate post-transplant phases, and have identified risk factors. Late post-transplant care could be improved by focus on groups at risk and better identification of infections of "unknown origin".

摘要

有关发病率和与死亡率相关的因素是改善造血干细胞移植(HSCT)后结局的前提。因此,在一项里程碑式分析中,对 114491 例接受 HSCT(83.7%为异基因)的白血病患者在第 30 天(极早期)、第 100 天(早期)、第 1 年(中期)和第 5 年(晚期)的死亡原因进行了调查。在自体 HSCT 后的所有移植后阶段,自队列 1(1980-2001 年)到队列 2(2002-2015 年),所有原因导致的死亡率均下降。异基因 HSCT 后,感染、GVHD 和毒性导致的死亡率在 1 年内下降,5 年内上升;移植后各阶段的复发死亡率均增加。不明原因的感染是感染性死亡的主要原因。从队列 1 到队列 2,致死性细菌和真菌感染减少,但不明原因或混合感染没有减少。感染性死亡与患者、疾病、供者类型、干细胞来源、中心和国家相关因素有关。它们的影响在移植后各阶段有所不同。移植中心成功地降低了 HSCT 后早期和中期的死亡率,并确定了风险因素。通过关注高危人群和更好地识别“不明原因”感染,可以改善晚期移植后的护理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d443/6957465/898045a9e8d2/41409_2019_624_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d443/6957465/db0dc64e6614/41409_2019_624_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d443/6957465/bee28b7116be/41409_2019_624_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d443/6957465/898045a9e8d2/41409_2019_624_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d443/6957465/db0dc64e6614/41409_2019_624_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d443/6957465/bee28b7116be/41409_2019_624_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d443/6957465/898045a9e8d2/41409_2019_624_Fig3_HTML.jpg

相似文献

1
Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors.造血干细胞移植后死亡:随时间推移的变化、感染及相关因素。
Bone Marrow Transplant. 2020 Jan;55(1):126-136. doi: 10.1038/s41409-019-0624-z. Epub 2019 Aug 27.
2
Allogeneic hematopoietic stem cell transplant recipients and parasitic diseases: A review of the literature of clinical cases and perspectives to screen and follow-up active and latent chronic infections.异基因造血干细胞移植受者与寄生虫病:临床病例文献综述及筛查与随访活动性和潜伏性慢性感染的展望
Transpl Infect Dis. 2017 Apr;19(2). doi: 10.1111/tid.12669. Epub 2017 Mar 31.
3
Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time.早期白血病异基因造血干细胞移植(HSCT)后的死亡原因:欧洲血液与骨髓移植组(EBMT)对致死性感染并发症及随日历时间变化情况的分析
Bone Marrow Transplant. 2005 Nov;36(9):757-69. doi: 10.1038/sj.bmt.1705140.
4
Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.来自匹配相关供体的异基因造血干细胞移植后晚期感染的危险因素。
Biol Blood Marrow Transplant. 2007 Nov;13(11):1304-12. doi: 10.1016/j.bbmt.2007.07.007. Epub 2007 Sep 7.
5
Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of "RISK" Study.韩国异基因造血干细胞移植受者侵袭性真菌病的流行病学和危险因素:“RISK”研究结果。
Biol Blood Marrow Transplant. 2017 Oct;23(10):1773-1779. doi: 10.1016/j.bbmt.2017.06.012. Epub 2017 Jun 28.
6
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.异基因造血干细胞移植后巨细胞病毒再激活与移植后存活至第100天的急性髓系白血病患者复发风险降低相关:日本造血细胞移植学会移植相关并发症工作组
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.
7
Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT.造血细胞移植后死因(COD)相关致死性感染并发症的减少:EBMT 传染病工作组的 COD-2 和 COD-1 研究。
Bone Marrow Transplant. 2023 Aug;58(8):881-892. doi: 10.1038/s41409-023-01998-2. Epub 2023 May 6.
8
Early infections after autologous hematopoietic stem cell transplantation in children and adolescents: the St. Jude experience.儿童和青少年自体造血干细胞移植后的早期感染:圣裘德儿童研究医院的经验
Transpl Infect Dis. 2014 Feb;16(1):90-7. doi: 10.1111/tid.12165. Epub 2013 Nov 21.
9
A review of infectious complications after haploidentical hematopoietic stem cell transplantations.单倍型相合造血干细胞移植后感染性并发症的综述
Infection. 2017 Aug;45(4):403-411. doi: 10.1007/s15010-017-1016-1. Epub 2017 Apr 17.
10
Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).异基因造血干细胞移植后侵袭性真菌病的发病率及转归:意大利骨髓移植协作组(GITMO)的一项前瞻性研究
Biol Blood Marrow Transplant. 2014 Jun;20(6):872-80. doi: 10.1016/j.bbmt.2014.03.004. Epub 2014 Mar 14.

引用本文的文献

1
Exercise Delays Human Leukemia Progression and Mitigates Graft-Versus-Host Disease After Donor Lymphocyte Infusion in Xenogeneic Mice.运动延缓异种基因小鼠中人类白血病进展,并减轻供体淋巴细胞输注后的移植物抗宿主病。
Cancers (Basel). 2025 Aug 29;17(17):2826. doi: 10.3390/cancers17172826.
2
Survival Prediction in Allogeneic Haematopoietic Stem Cell Transplant Recipients Using Pre- and Post-Transplant Factors and Computational Intelligence.利用移植前后因素和计算智能预测异基因造血干细胞移植受者的生存情况
J Cell Mol Med. 2025 Aug;29(16):e70672. doi: 10.1111/jcmm.70672.
3
A higher ratio of IL-2/IL-4 may be an early predictor of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

本文引用的文献

1
Infectious complications of marrow transplant: risk factors for infection.骨髓移植的感染并发症:感染的危险因素
Prog Clin Biol Res. 1989;309:357-66.
白细胞介素-2与白细胞介素-4的比例较高可能是异基因造血干细胞移植后急性移植物抗宿主病的早期预测指标。
Front Immunol. 2025 Jul 11;16:1620761. doi: 10.3389/fimmu.2025.1620761. eCollection 2025.
4
Assessing Social Determinants of Health in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT.评估移植和CAR-T治疗受者的健康社会决定因素:美国血液与骨髓移植学会生存特别兴趣小组的专家小组建议
Transplant Cell Ther. 2025 Jul 23. doi: 10.1016/j.jtct.2025.07.017.
5
Culturing Potential: advances in ex vivo cell culture systems for haematopoietic cell-based regenerative therapies.培养潜力:用于基于造血细胞的再生疗法的体外细胞培养系统的进展
Regen Ther. 2025 Jul 17;30:403-414. doi: 10.1016/j.reth.2025.07.001. eCollection 2025 Dec.
6
Microbiome-based prediction of allogeneic hematopoietic stem cell transplantation outcome.基于微生物组对异基因造血干细胞移植结果的预测
Genome Med. 2025 Jul 17;17(1):80. doi: 10.1186/s13073-025-01507-8.
7
High infection rates and risk-adapted prevention strategies in contemporary pediatric allogeneic hematopoietic stem cell transplantation.当代儿科异基因造血干细胞移植中的高感染率及风险适应性预防策略
Pediatr Discov. 2024 Jul 14;2(4):e101. doi: 10.1002/pdi3.101. eCollection 2024 Dec.
8
Perception of 'patient safety culture' among healthcare professionals in the field of haematopoietic stem cell transplantation and CAR-T therapy: a multicentre cross-sectional observational study by Italian Transplant Group for Bone Marrow Transplantation, Haematopoietic Stem Cells and Cell Therapy (GITMO).造血干细胞移植和嵌合抗原受体T细胞疗法领域医护人员对“患者安全文化”的认知:意大利骨髓移植、造血干细胞及细胞治疗移植组(GITMO)的多中心横断面观察研究
BMJ Open Qual. 2025 Jul 7;14(3):e003318. doi: 10.1136/bmjoq-2025-003318.
9
Healthcare Resource Use and Costs of Allogeneic Hematopoietic Stem Cell Transplantation Complications: A Scoping Review.异基因造血干细胞移植并发症的医疗资源使用与成本:一项范围综述
Curr Oncol. 2025 May 16;32(5):283. doi: 10.3390/curroncol32050283.
10
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple Myeloma.靶向晚期多发性骨髓瘤中C-X-C基序趋化因子受体4的清髓性放射性配体疗法
Clin Nucl Med. 2025 Jun 1;50(6):495-500. doi: 10.1097/RLU.0000000000005813. Epub 2025 Mar 5.